Sonnet BioTherapeutics Holdings, Inc. (SONN)

US — Healthcare Sector
Peers: EFTR  ZURA  NAVB  ZVSA  ADTX  SNOA  HOTH  WORX  NAOV 

Automate Your Wheel Strategy on SONN

With Tiblio's Option Bot, you can configure your own wheel strategy including SONN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SONN
  • Rev/Share 0.255
  • Book/Share 0.1689
  • PB 19.6597
  • Debt/Equity 0.1366
  • CurrentRatio 1.0265
  • ROIC -16.5417

 

  • MktCap 20797044.0
  • FreeCF/Share -2.9664
  • PFCF -1.7877
  • PE -0.98
  • Debt/Assets 0.0236
  • DivYield 0
  • ROE -7.7796

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

This stock rockets 260% after $900 million mega crypto deal
SONN
Published: July 14, 2025 by: Finbold
Sentiment: Positive

Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the company announced a $888 million business combination to pivot into the cryptocurrency sector.

Read More
image for news This stock rockets 260% after $900 million mega crypto deal
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
SONN
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet shareholders. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. Halper Sadeh encourages Sonnet shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sa.

Read More
image for news SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
SONN
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury

Read More
image for news Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
Sonnet Releases Virtual Investor "What This Means" Segment
SONN
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010

Read More
image for news Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
SONN
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )

Read More
image for news Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
SONN
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® ) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 American Association for Cancer Research (AACR) IO Conference.

Read More
image for news Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
SONN
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)

Read More
image for news Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
SONN
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR)

Read More
image for news Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

About Sonnet BioTherapeutics Holdings, Inc. (SONN)

  • IPO Date 2006-10-31
  • Website https://www.sonnetbio.com
  • Industry Biotechnology
  • CEO Raghu Rao
  • Employees 13

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.